5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

摘要

This invention is directed to the use of dihydropyrimidine compounds, which are selective antagonists for cloned human alpha1C receptors, for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human alpha1C receptor is useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-identified compounds and a pharmaceutically acceptable carrier.